Brain-computer interface (BCI) technology is moving from surgical implants to everyday consumer devices. Neurable, a startup specializing in non-invasive neural sensing, announced this week that it's licensing its "mind-reading" technology to consumer wearables manufacturers, marking a significant shift in how brain data could be collected and used in daily life.

What Makes Neurable's Approach Different From Neuralink?

While companies like Neuralink require brain surgery to implant computer chips directly into the skull, Neurable's technology works through external sensors. The company uses electroencephalography (EEG) sensors combined with artificial intelligence signal processing to scan brain activity, analyze it, and provide insights about cognitive performance without any invasive procedures. This non-invasive approach removes a major barrier to adoption, since users don't need to undergo surgery to benefit from the technology.

In December, Neurable raised $35 million in Series A funding, which the company is using to scale commercialization efforts. The licensing announcement represents the next phase of that expansion strategy, opening the door for hardware manufacturers to integrate neural sensing into products consumers already use daily.

How Could Brain-Sensing Technology Be Used in Consumer Products?

Neurable's licensing platform allows original equipment manufacturers (OEMs) to integrate the company's AI-powered brain-sensing technology directly into existing hardware while maintaining control over product design and user experience. The potential applications span multiple industries:

• Gaming and Performance: Neurable has already partnered with HP Inc.'s HyperX gaming brand to create a headset designed to help gamers optimize focus and performance during gameplay.
• Health and Athletic Products: Neural data could be integrated into fitness wearables and health monitoring devices to track cognitive load and mental fatigue alongside physical metrics.
• Productivity Tools: Workplace applications could use brain-sensing data to help workers understand their concentration levels and optimize work schedules.
• Research Platforms: Neurable has partnered with iMotions, a software platform specializing in human behavior research, to support research initiatives using neural data.

The vision is ambitious: Neurable's CEO Ramses Alcaide stated that the company wants to make neural sensors "as ubiquitous as heart rate sensors on your wrist". This would mean brain-sensing technology becoming a standard feature across multiple consumer device categories.

Ramses Alcaide

What Privacy Protections Exist for Brain Data?

Brain data is arguably more intimate than heart rate information, raising legitimate privacy concerns. Neurable says it follows Health Insurance Portability and Accountability Act (HIPAA) standards and goes beyond what many startups at its stage typically implement. The company encrypts data, anonymizes it, and requires explicit user consent before using neural data to train its AI systems.

"We make sure we follow HIPAA standards, like we've gone above and beyond where a lot of startups would be at our stage to make sure that we protect the data, we encrypt it, and that we anonymize it," said Ramses Alcaide, CEO of Neurable.

Ramses Alcaide, CEO at Neurable

Alcaide emphasized that the company doesn't collect and train on user data indiscriminately. Instead, data usage is targeted and specific, with users asked whether their information can be used for particular experiments. This consent-based approach differs from how some tech companies handle user data, though privacy advocates will likely continue scrutinizing how neural information is handled as the technology scales.

What's the Timeline for Commercial Availability?

Neurable has already demonstrated proof of concept through partnerships with established companies like HyperX. The startup is now in an expansion phase, seeking to broaden its partnerships across multiple industries and use cases. Alcaide declined to disclose specific new partnerships in development, but indicated the company is focused on scaling rapidly now that it has proven the technology works across different applications.

The broader context matters here: brain-computer interface technology is experiencing a genuine inflection point. Alcaide noted that the industry has finally reached a stage where "there exists a real business model in neuro-technology that is scalable". This suggests that consumer brain-sensing products could begin appearing in the market within the next few years, not decades.

Alcaide

How Does This Compare to Other BCI Developments?

Neurable's non-invasive approach contrasts sharply with invasive BCI research happening elsewhere. Meanwhile, other therapeutic applications of brain-computer interfaces are advancing through clinical trials. Motif Neurotech, a company commercializing technology from Rice University research, recently received FDA approval to begin clinical trials of an implantable BCI device designed to treat treatment-resistant depression. That device, called DOT (Digitally Programmable Over-brain Therapeutic), is about the size of a blueberry and sits in the skull above the protective brain membrane without touching brain tissue directly.

"The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes," explained Jacob Robinson, professor of electrical and computer engineering and bioengineering at Rice and co-founder and CEO of Motif.

Jacob Robinson, Professor of Electrical and Computer Engineering and Bioengineering at Rice University

Motif obtained FDA approval for its investigational device exemption just four years after its founding, a record timeline for a BCI company. The clinical trial will enroll adults whose depression hasn't improved after multiple therapies and will be conducted across leading medical institutions including Baylor College of Medicine, Massachusetts General Brigham, and Emory Healthcare. The company was also selected for ARPA-H's (Advanced Research Projects Agency for Health) EVIDENT program, which will fund collection of additional data to identify which patients respond best to neuromodulation treatments.

The contrast between Neurable and Motif illustrates the current state of BCI development: non-invasive consumer applications are scaling through licensing partnerships, while invasive therapeutic devices are advancing through rigorous clinical validation for specific medical conditions. Both approaches are progressing simultaneously, suggesting that brain-computer interface technology is transitioning from experimental research into practical deployment across multiple domains.